



Immedica appoints Daniel Camardo as President of Immedica North America

Stockholm, September 17, 2024 – Immedica Pharma AB announces today the appointment of Daniel Camardo as President of Immedica North America and member of the company’s executive team.

Mr. Camardo has more than 25 years of industry leadership experience spanning from small emerging biotech to mid-size rare disease and large multi-national companies and has contributed to the successful launch of multiple blockbuster medicines (>\$1B annual net sales) and more than 14 BLAs and NDAs across the therapeutic areas Oncology, Rheumatology, Immunology, Neurology, Dermatology, Urology, and Metabolic Diseases.

Daniel Camardo will be responsible for the establishment of a commercial infrastructure for Immedica in the North America and the recruitment of a team.

Anders Edvell, CEO of Immedica, commented: “Daniel is an experienced executive leader who has a passion for rare diseases and a deep understanding about building high performing teams and launching rare disease products in North America”.

“Daniel’s extensive industry experience includes transforming single product start-ups into high-functioning multi-franchise organizations. His breadth of skills and experience combined with his respected leadership and team-building style will be valuable to Immedica as our company enters the next exciting phase of its evolution,” concluded Anders Edvell.

Daniel Camardo, President Immedica North America, said: “I’m excited to join Immedica at this pivotal time and lead the development of a U.S. commercial organization. I look forward to working closely with our European colleagues and U.S. employees to develop Immedica into a global leader in rare disease”.

Prior to joining Immedica, Daniel was a strategic advisor at CLC Biopharma and CEO of Athersys, focusing on innovative cell therapies. He held key executive roles at Horizon Therapeutics, driving its transformation into a rare disease leader. He also led commercial growth at Clarus Therapeutics and Astellas Pharma. Daniel holds an MBA from Northwestern University and is a Board Member at CommunityHealth.

About Immedica

Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 120 people in Europe, the Middle East and the U.S.

For more information visit www.immedica.com

Immedica contact:

Linda Holmström

Head of Communication

linda.holmstrom@immedica.com

+ 46 708 73 40 95